Literature DB >> 12960209

Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma.

C M Drovdlic1, K A B Goddard, A Chak, W Brock, L Chessler, J F King, J Richter, G W Falk, D K Johnston, J L Fisher, W M Grady, S Lemeshow, C Eng.   

Abstract

BACKGROUND: Based on reported familial patterns, inheritance of a predisposition of developing Barrett's oesesophagus (BO) and oesophageal adenocarcinoma (OAC) likely follows an autosomal dominant model of most inherited cancer syndromes. oesophagus (BO) and oesophageal adenocarcinoma (OAC) likely follows an autosomal dominant model of most inherited cancer syndromes. AIMS: We analysed the phenotypic features of 70 familial BO/OAC families accrued for the purpose of initiating a linkage study to search for genes that contribute to susceptibility for BO/OAC.
METHODS: Families with young or familial BO/OAC were recruited from participating institutions and self-referral from advertisement.
RESULTS: A total of 70 families (173 affected and 784 unaffected individuals) were recruited into this study. Mean ages of diagnosis of BO and OAC among males were 50.6 and 57.4 years, respectively; among females, 52.1 and 63.5 years, respectively. The standardised incidence ratio (SIR) of cancers other than OAC or oesophagogastric junctional adenocarcinoma (OGJAC), among probands was 0.71. Seventy one percent of the pedigrees have "typical" structures with less than three affected individuals. Power calculations under realistic model assumptions suggest that if genetic heterogeneity is absent or limited, then DNA collection from members of these pedigrees could enable the identification of a novel candidate susceptibility gene for BO/OAC in a genome scan.
CONCLUSIONS: This is the largest series of families with BO/OAC yet reported, features of which are consistent with inherited germline predisposition. Further, the SIR of cancers other than OAC/OGJAC was 0.71 among 70 probands, indicating these individuals were not more likely to develop non-OAC cancers.

Entities:  

Mesh:

Year:  2003        PMID: 12960209      PMCID: PMC1735581          DOI: 10.1136/jmg.40.9.651

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  19 in total

1.  Familial clustering of reflux symptoms.

Authors:  N J Trudgill; K C Kapur; S A Riley
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

2.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

3.  Carcinoma arising in familial Barrett's esophagus.

Authors:  A R Poynton; T N Walsh; G O'Sullivan; T P Hennessy
Journal:  Am J Gastroenterol       Date:  1996-09       Impact factor: 10.864

4.  Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction.

Authors:  C Eng; S J Spechler; R Ruben; F P Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Jul-Aug       Impact factor: 4.254

5.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

6.  Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Y Romero; A J Cameron; G R Locke; D J Schaid; J M Slezak; C D Branch; L J Melton
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

7.  Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett.

Authors:  J M Cauvin; D Goldfain; M Le Rhun; M Robaszkiewicz; G Cadiot; S Carpentier; A Rotenberg; M Mignon; J Boyer; J P Galmiche
Journal:  Lancet       Date:  1995-11-25       Impact factor: 79.321

8.  Barrett's esophagus: an acquired condition with genetic predisposition.

Authors:  N Fahmy; J F King
Journal:  Am J Gastroenterol       Date:  1993-08       Impact factor: 10.864

9.  Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs.

Authors:  G Morgan; H Vainio
Journal:  Eur J Cancer Prev       Date:  1998-06       Impact factor: 2.497

Review 10.  A systematic review of the association between Barrett's esophagus and colon neoplasms.

Authors:  C W Howden; C A Hornung
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

View more
  14 in total

1.  Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Amitabh Chak; Gary Falk; William M Grady; Margaret Kinnard; Robert Elston; Sumeet Mittal; James F King; Joseph E Willis; Anokh Kondru; Wendy Brock; Jill Barnholtz-Sloan
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

Review 2.  The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective.

Authors:  Henry To; Nicholas J Clemons; Cuong P Duong; Alison H Trainer; Wayne A Phillips
Journal:  Dig Dis Sci       Date:  2016-03-12       Impact factor: 3.199

3.  Comparison of endoscopic and clinical characteristics of patients with familial and sporadic Barrett's esophagus.

Authors:  Samuel Ash; Benjamin J Vaccaro; Mary Kay Dabney; Wendy K Chung; Charles J Lightdale; Julian A Abrams
Journal:  Dig Dis Sci       Date:  2011-02-24       Impact factor: 3.199

4.  Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma.

Authors:  Mohammed Orloff; Charissa Peterson; Xin He; Shireen Ganapathi; Brandie Heald; Yi-ran Yang; Gurkan Bebek; Todd Romigh; Jee Hoon Song; Wenjing Wu; Stefan David; Yulan Cheng; Stephen J Meltzer; Charis Eng
Journal:  JAMA       Date:  2011-07-27       Impact factor: 56.272

5.  Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus.

Authors:  Amitabh Chak; Yanwen Chen; Jaime Vengoechea; Marcia I Canto; Robert Elston; Gary W Falk; William M Grady; Kishore Guda; Margaret Kinnard; Sanford Markowitz; Sumeet Mittal; Ganapathy Prasad; Nicholas Shaheen; Joseph E Willis; Jill S Barnholtz-Sloan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-16       Impact factor: 4.254

Review 6.  Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.

Authors:  Sumeet K Mittal; Joe Abdo; Malika P Adrien; Binyam A Bayu; Jay R Kline; Molly M Sullivan; Devendra K Agrawal
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 7.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Authors:  Brian J Reid; Xiaohong Li; Patricia C Galipeau; Thomas L Vaughan
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 8.  Barrett's oesophagus: an ideal model to study cancer genetics.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  Hum Genet       Date:  2009-04-14       Impact factor: 4.132

Review 9.  Hereditary Factors in Esophageal Adenocarcinoma.

Authors:  Anna M J van Nistelrooij; Winand N M Dinjens; Anja Wagner; Manon C W Spaander; J Jan B van Lanschot; Bas P L Wijnhoven
Journal:  Gastrointest Tumors       Date:  2014-05-09

10.  Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.

Authors:  Zhan Su; Laura J Gay; Amy Strange; Claire Palles; Gavin Band; David C Whiteman; Francesco Lescai; Cordelia Langford; Manoj Nanji; Sarah Edkins; Anouk van der Winkel; David Levine; Peter Sasieni; Céline Bellenguez; Kimberley Howarth; Colin Freeman; Nigel Trudgill; Art T Tucker; Matti Pirinen; Maikel P Peppelenbosch; Luc J W van der Laan; Ernst J Kuipers; Joost P H Drenth; Wilbert H Peters; John V Reynolds; Dermot P Kelleher; Ross McManus; Heike Grabsch; Hans Prenen; Raf Bisschops; Kausila Krishnadath; Peter D Siersema; Jantine W P M van Baal; Mark Middleton; Russell Petty; Richard Gillies; Nicola Burch; Pradeep Bhandari; Stuart Paterson; Cathryn Edwards; Ian Penman; Kishor Vaidya; Yeng Ang; Iain Murray; Praful Patel; Weimin Ye; Paul Mullins; Anna H Wu; Nigel C Bird; Helen Dallal; Nicholas J Shaheen; Liam J Murray; Konrad Koss; Leslie Bernstein; Yvonne Romero; Laura J Hardie; Rui Zhang; Helen Winter; Douglas A Corley; Simon Panter; Harvey A Risch; Brian J Reid; Ian Sargeant; Marilie D Gammon; Howard Smart; Anjan Dhar; Hugh McMurtry; Haythem Ali; Geoffrey Liu; Alan G Casson; Wong-Ho Chow; Matt Rutter; Ashref Tawil; Danielle Morris; Chuka Nwokolo; Peter Isaacs; Colin Rodgers; Krish Ragunath; Chris MacDonald; Chris Haigh; David Monk; Gareth Davies; Saj Wajed; David Johnston; Michael Gibbons; Sue Cullen; Nicholas Church; Ruth Langley; Michael Griffin; Derek Alderson; Panos Deloukas; Sarah E Hunt; Emma Gray; Serge Dronov; Simon C Potter; Avazeh Tashakkori-Ghanbaria; Mark Anderson; Claire Brooks; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden Corvin; Audrey Duncanson; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Ananth C Viswanathan; Nicholas Wood; Gosia Trynka; Cisca Wijmenga; Jean-Baptiste Cazier; Paul Atherfold; Anna M Nicholson; Nichola L Gellatly; Deborah Glancy; Sheldon C Cooper; David Cunningham; Tore Lind; Julie Hapeshi; David Ferry; Barrie Rathbone; Julia Brown; Sharon Love; Stephen Attwood; Stuart MacGregor; Peter Watson; Scott Sanders; Weronica Ek; Rebecca F Harrison; Paul Moayyedi; John de Caestecker; Hugh Barr; Elia Stupka; Thomas L Vaughan; Leena Peltonen; Chris C A Spencer; Ian Tomlinson; Peter Donnelly; Janusz A Z Jankowski
Journal:  Nat Genet       Date:  2012-09-09       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.